Prevalence of drug-resistant mutations in newly diagnosed drug-naïve HIV-1-infected individuals in a treatment site in the Waterberg district, Limpopo province

South African Medical Journal

Volumn 101, Issue 5, 2011, Pages 335-337

  Nwobegahay, Julius ^a   Bessong, Pascal ^a   Masebe, Tracy ^a   Mavhandu, Lufuno ^a   Manhaeve, Cecile ^b   Ndjeka, Norbert ^b   Selabe, Gloria ^c  

^a UNIVERSITY OF VENDA   (South Africa)

^b The HIV/AIDS Prevention Group   (South Africa)

^c UNIVERSITY OF LIMPOPO   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DURANAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; LOPINAVIR PLUS RITONAVIR; PROTEINASE; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; SOUTH AFRICA; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS MUTATION;

EID: 79957442078     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/samj.4391     Document Type: Article

References (12)

1. Gatanaga H, Ibe S, Matsuda M, et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res 2007;75:75-78.
2. Turner D, Wainberg MA. HIV transmission and primary drug resistance. AIDS Rev 2006;8:17-23.
3. Bessong PO, Mphahlele J, Choge IA, et al. Resistance mutational analysis of HIV type 1 subtype c among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses 2006;22(12):1306-1312.
4. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Topics HIV Med 2009;17(5):138-145.
5. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naïve HIV-1- infected individuals in Gauteng province, South Africa in 2002 and 2004. Antivir Ther 2008;2:101-107.
6. Jacobs GB, Laten A, van Rensburg EJ, et al. Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naïve patients from Cape Town, South Africa. AIDS Res Hum Retroviruses 2008;1009-1012.
7. Orrell C, Walensky RP, Losina E, Freedberg KA, Wood R. HIV-1 Clade C resistance genotypes after first virological failure in a large community ART programme. J Int AIDS Soc 2008;11:1758.
8. Handema R, Terunuma, H, Kasolo F, et al. Prevalence of drug resistance associated mutations in antiretroviral drug naïve Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses 2003;19:151-160.
9. Kamoto K, Aberle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008;2:83-87.
10. Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2006;21:179-180.
11. Taiwo B. Understanding transmitted HIV resistance through the experience in the USA. J Inf Dis 2008;10:1-8.
12. Department of Health. National Antiretroviral Treatment Guidelines. Pretoria: Department of Health, 2004.